PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Justin F. Gainor, MD - New Frontiers in Precision Immuno-Oncology: Leveraging Biomarkers to Refine and Expand the Use of Cancer Immunotherapies and Combinations
Go online to PeerView.com/FQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As a result of intense research efforts, the foundational understanding of the interplay between cancer and immunity and how to harness it for therapeutic benefit is deepening. As the evidence base grows exponentially, the treatment landscape is becoming more complicated, highlighting the need for precision approaches to maximize the potential of immuno-oncology. In this activity, based on a recent live symposium held in San Francisco, CA, experts in immuno-oncology explore the latest evidence and data on the present and future of cancer immunotherapies and biomarkers, debate critical issues, and share practical guidance that you can use in the care of your patients with cancer. Upon completion of this activity, participants will be able to: Review the most up-to-date evidence and mechanistic understanding supporting the use of current and emerging cancer immunotherapies, including single-agent and combination approaches, across a spectrum of different malignancies, Evaluate the latest evidence on the role and use of established, novel, and emerging cancer immunotherapy biomarkers (eg, PD-L1, MSI/MMR, TMB, TILs, LAG-3, composite biomarkers, et cetera), Integrate into practice up-to-date cancer immunotherapy biomarker testing approaches and immune-based therapies/combinations according to the latest evidence, recommendations, and principles of precision immuno-oncology.